EverSource Wealth Advisors LLC Buys 947 Shares of Exelixis, Inc. (NASDAQ:EXEL)

EverSource Wealth Advisors LLC boosted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 40.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,269 shares of the biotechnology company’s stock after acquiring an additional 947 shares during the period. EverSource Wealth Advisors LLC’s holdings in Exelixis were worth $109,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of EXEL. USA Financial Formulas bought a new position in shares of Exelixis during the 4th quarter valued at about $32,000. Principal Securities Inc. boosted its stake in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. Kestra Investment Management LLC purchased a new position in Exelixis during the 4th quarter valued at approximately $39,000. Brooklyn Investment Group bought a new stake in Exelixis in the 3rd quarter worth approximately $42,000. Finally, UMB Bank n.a. raised its holdings in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Exelixis news, Director Bob Oliver sold 18,647 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now owns 33,514 shares of the company’s stock, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last three months. 2.85% of the stock is owned by company insiders.

Exelixis Stock Performance

Exelixis stock opened at $36.36 on Wednesday. The company has a market capitalization of $10.18 billion, a PE ratio of 20.54, a P/E/G ratio of 1.13 and a beta of 0.57. The company has a 50 day moving average price of $35.48 and a 200-day moving average price of $32.68. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. UBS Group boosted their target price on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Brookline Capital Management started coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating and set a $42.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $30.00 to $40.00 in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average price target of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.